# LY6E as a new prognostic biomarker of multiple myeloma-related bone disease

## TL;DR

This study identifies LY6E as a potential biomarker and therapeutic target for multiple myeloma-related bone disease.

## Contribution

The study introduces LY6E as a novel prognostic biomarker for multiple myeloma-related bone disease.

## Key findings

- Higher LY6E expression is linked to MM progression and poor prognosis.
- LY6E promotes MM cell proliferation and osteoclast differentiation in vitro.

## Abstract

Osteolytic bone disease, which deteriorates the quality of life, is a prevalent complication of multiple myeloma (MM). In this study, we utilized bioinformatics analysis to identify the differentially expressed genes (DEGs) associated with MM bone disease (MBD) from the Gene Expression Omnibus (GEO) databases. Here, the Kaplan-Meier (K-M) curve and Cox regression analyses demonstrated that the key molecule lymphocyte antigen 6 complex (LY6E) was closely correlated with the MM progression, unfavorable prognosis and the formation of MBD. Furthermore, we confirmed that higher LY6E expression promoted MM cell proliferation and osteoclast differentiation in vitro. Taken together, these findings may illuminate the theoretical foundation for LY6E in MBD formation and identify it as a neoteric therapeutic target for MM.

The online version contains supplementary material available at 10.1038/s41598-025-91413-1.